Author: Zheng, Shaoping; Chen, Qiaosen; Jiang, Hongbo; Guo, Chunxia; Luo, Jinzhuo; Li, Sumeng; Wang, Hua; Li, Huadong; Zheng, Xin; Weng, Zhihong
Title: No significant benefit of moderate-dose vitamin C on severe COVID-19 cases Cord-id: kv57il55 Document date: 2021_9_22
ID: kv57il55
Snippet: There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause de
Document: There is no specific drug for coronavirus disease 2019 (COVID-19). We aimed to investigate the possible clinical efficacy of moderate-dose vitamin C infusion among inpatients with severe COVID-19. Data of 397 adult patients with severe COVID-19 admitted to a designated clinical center of Wuhan Union Hospital (China) between February 13 and February 29, 2020, were collected. Besides standard therapies, patients were treated with vitamin C (2–4 g/day) or not. The primary outcome was all-cause death. Secondary outcome was clinical improvement of 2 points on a 6-point ordinal scale. About 70 participants were treated with intravenous vitamin C, and 327 did not receive it. No significant association was found between vitamin C use and death on inverse probability treatment weighting (IPTW) analysis (weighted hazard ratio [HR], 2.69; 95% confidence interval [CI], 0.91–7.89). Clinical improvement occurred in 74.3% (52/70) of patients in the vitamin C group and 95.1% (311/327) in the no vitamin C group. No significant difference was observed between the two groups on IPTW analysis (weighted HR, 0.76; 95% CI, 0.55–1.07). Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement.
Search related documents:
Co phrase search for related documents- abdominal pain and acute inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abdominal pain and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- abdominal pain and lung injury: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and admission start: 1
- acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lung capillary: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute inflammatory and admission start: 1
- acute inflammatory and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute inflammatory and low molecular weight heparin: 1, 2, 3, 4
- acute inflammatory and lung capillary: 1, 2, 3, 4
- admission severe type and logistic regression: 1, 2
- admission start and logistic regression: 1, 2, 3
- live discharge and logistic regression: 1
- logistic regression and low molecular weight heparin: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date